Background and purpose To analyze outcomes of non-small cell lung cancer (NSCLC)
patients with brain metastases harboring EGFR or ALK mutations and examine for …

Background The role for radiotherapy or surgery in the upfront management of brain
metastases (BrM) in epidermal growth factor receptor mutant (EGFRm) or anaplastic …

Opinion statement Management of non-small cell lung cancer (NSCLC) with brain
metastasis (BrM) has been revolutionized by identification of molecular subsets that have …

Background The impact of activating alterations in non–small cell lung cancer
(NSCLC)(epidermal growth factor receptor [EGFR] mutation/anaplastic lymphoma kinase …

Background The treatment options for epidermal growth factor receptor (EGFR)‐mutated
non‐small cell lung cancer (NSCLC) with brain metastases (BMs) include EGFR‐tyrosine …

Introduction Brain metastases in EGFR/ALK-driven NSCLC frequently pose treatment
dilemmas. Tyrosine kinase inhibitors (TKIs) can control extracranial disease, but …

Purpose Stereotactic radiosurgery (SRS), whole-brain radiotherapy (WBRT), and epidermal
growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are treatment options for …

Background We investigated effects of genetic alterations in epidermal growth factor
receptor (EGFR), anaplastic lymphoma kinase (ALK), and Kirsten rat sarcoma viral …

Introduction Brain metastases are one of the leading causes of death from non-small-cell
lung cancer (NSCLC). The use of epidermal growth factor receptor (EGFR) tyrosine kinase …

Background We determined the impact of genetic alterations in EGFR, ALK, or KRAS on
survival after radiotherapy for brain metastases in non–small cell lung cancer (NSCLC) …